Novartis Foradil Heart Monitoring Phase IV Required With COPD Approval
Executive Summary
Novartis will conduct holter heart monitoring in Foradil Aerolizer patients as a Phase IV commitment following the approval of formoterol for chronic obstructive pulmonary disease Sept. 25.
You may also be interested in...
Sepracor’s Brovana COPD Therapy Approved; Launch Planned For 2007
Sepracor's newly approved long-acting beta2-agonist for chronic obstructive pulmonary disease appears to have a slower onset of effect than Novartis/Schering-Plough's Foradil
Sepracor’s Brovana COPD Therapy Approved; Launch Planned For 2007
Sepracor's newly approved long-acting beta2-agonist for chronic obstructive pulmonary disease appears to have a slower onset of effect than Novartis/Schering-Plough's Foradil
Novartis Foradil Higher-Dose Phase IV Studies Slated For Completion By 2003
Novartis will study higher doses of Foradil (formoterol) as a postmarketing commitment associated with FDA's Feb. 16 approval of the asthma therapy.